No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

被引：0
|
作者：
Deodhar, Atul A. [1 ]
Schreiber, Stefan [2 ]
Gandhi, Kunal [3 ]
Fox, Todd [4 ]
Gaillez, Corine [4 ]
Karyekar, Chetan [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Christian Albrechts Univ Kiel, Kiel, Germany
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
962
引用
收藏
页数：3
相关论文
共 50 条
  • [1] NO INCREASED RISK OF INFLAMMATORY BOWEL DISEASE AMONG SECUKINUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PSORIASIS, PSORIATIC ARTHRITIS, OR ANKYLOSING SPONDYLITIS: DATA FROM 14 PHASE 2 AND PHASE 3 CLINICAL STUDIES
    Zochling, J.
    Deodhar, A.
    Schreiber, S.
    Gandhi, K.
    Fox, T.
    Gaillez, C.
    Karyekar, C.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 38 - 39
  • [2] NO INCREASED INCIDENCE OF INFLAMMATORY BOWEL DISEASE AMONG SECUKINUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PSORIASIS, PSORIATIC ARTHRITIS, OR ANKYLOSING SPONDYLITIS: DATA FROM 14 PHASE 2 AND PHASE 3 CLINICAL STUDIES
    Schreiber, S.
    Sands, B. E.
    Deodhar, A.
    Baeten, D.
    Huang, J.
    Gandhi, K.
    Karyekar, C.
    Fox, T.
    Gaillez, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 97 - 98
  • [3] The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis
    van de Kerkhof, P. C. M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (05) : 879 - 879
  • [4] INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN PATIENTS TREATED WITH SECUKINUMAB: POOLED ANALYSIS OF 21 RANDOMISED CONTROLLED PHASE 3/ 4 CLINICAL TRIALS OF PSORIASIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
    Schreiber, Stefan
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Reich, Kristian
    Deodhar, Atul
    McInnes, Iain B.
    Porter, Brian
    Das Gupta, Ayan
    Pricop, Luminita
    Fox, Todd
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 18 - 18
  • [5] Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
    Deodhar, Atul A.
    Miceli-Richard, Corine
    Baraliakos, Xenofon
    Marzo-Ortega, Helena
    Gladman, Dafna D.
    Blanco, Ricardo
    Das Gupta, Ayan
    Martin, Ruvie
    Safi, Jorge
    Porter, Brian
    Shete, Abhijit
    Rosenbaum, James T.
    [J]. ACR OPEN RHEUMATOLOGY, 2020, 2 (05) : 294 - 299
  • [6] Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
    Schreiber, Stefan
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Reich, Kristian
    Deodhar, Atul A.
    McInnes, Iain B.
    Porter, Brian
    Das Gupta, Ayan
    Pricop, Luminita
    Fox, Todd
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (04) : 473 - 479
  • [7] The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up
    Lebwohl, M.
    Deodhar, A.
    Griffiths, C. E. M.
    Menter, M. A.
    Poddubnyy, D.
    Bao, W.
    Jehl, V.
    Marfo, K.
    Primatesta, P.
    Shete, A.
    Trivedi, V.
    Mease, P. J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (05) : 935 - 944
  • [8] Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
    Kiltz, Uta
    Sfikakis, Petros P.
    Gaffney, Karl
    Sator, Paul-Gunther
    von Kiedrowski, Ralph
    Bounas, Andreas
    Gullick, Nicola
    Conrad, Curdin
    Rigopoulos, Dimitris
    Lespessailles, Eric
    Romanelli, Marco
    Ghislain, Pierre-Dominique
    Brandt-Juergens, Jan
    Rashkov, Rasho
    Aassi, Maher
    Orsenigo, Roberto
    Perella, Chiara
    Pournara, Effie
    Gathmann, Sven
    Jagiello, Piotr
    Veit, Justyna
    Augustin, Matthias
    [J]. ADVANCES IN THERAPY, 2020, 37 (06) : 2865 - 2883
  • [9] Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
    Uta Kiltz
    Petros P. Sfikakis
    Karl Gaffney
    Paul-Gunther Sator
    Ralph von Kiedrowski
    Andreas Bounas
    Nicola Gullick
    Curdin Conrad
    Dimitris Rigopoulos
    Eric Lespessailles
    Marco Romanelli
    Pierre-Dominique Ghislain
    Jan Brandt-Jürgens
    Rasho Rashkov
    Maher Aassi
    Roberto Orsenigo
    Chiara Perella
    Effie Pournara
    Sven Gathmann
    Piotr Jagiello
    Justyna Veit
    Matthias Augustin
    [J]. Advances in Therapy, 2020, 37 : 2865 - 2883
  • [10] Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
    Mease, Philip J.
    Lebwohl, Mark
    Gilloteau, Isabelle
    Fox, Todd
    Oliver, Jaime
    Jugl, Steffen
    Gottlieb, Alice B.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
12345